Potential Nomenclature Errors
The term "GATL7" may stem from typographical or transcriptional errors. Closest matches in existing literature include:
| Potential Target | Relevance to Query | Key Citations |
|---|
| Galectin-7 (GAL7) | A β-galactoside-binding protein involved in apoptosis, cell differentiation, and cancer. Anti-GAL7 antibodies (e.g., MAB13392) are used in research. | |
| GATM (Glycine Amidinotransferase) | Mitochondrial enzyme linked to creatine synthesis. Commercial antibodies exist for research use (e.g., HPA validation data). | |
Galectin-7 Antibody (MAB13392)
This monoclonal antibody targets human Galectin-7 and has been validated in multiple applications:
Research Applications
| Application | Protocol | Key Findings |
|---|
| Western Blot | Detects endogenous GAL7 (~14 kDa) in human skin and cancer tissues. | Strong specificity in skin cancer lysates . |
| Immunohistochemistry | Localizes GAL7 in cervical cancer cytoplasm/nuclei (5 µg/mL concentration). | Overexpression correlates with tumor progression . |
| Flow Cytometry | Intracellular staining in A431 epithelial carcinoma cells (2 µg/mL antibody). | Confirmed cytoplasmic expression . |
Clinical Relevance
GATM Antibody (HPA Data)
Antibodies against Glycine Amidinotransferase (GATM) are used in metabolic studies:
Validation Metrics
| Assay Type | Result | Consistency |
|---|
| Immunocytochemistry | Supported (cell line validation) | High |
| Western Blot | Uncertain (low specificity in tissue panels) | Low |
| Protein Array | Approved (384-antigen specificity test) | Medium |
Technical Considerations
Misinterpretations in antibody nomenclature often arise from:
-
Acronym confusion: "GATL7" vs. established symbols (e.g., GAL7, GATM).
-
Species specificity: Many antibodies are species-restricted (e.g., human vs. murine).
-
Epitope variability: Commercial antibodies target specific isoforms or post-translational modifications .
Recommendations for Further Research
-
Verify the intended target (e.g., GAL7, GATM, or novel epitopes).
-
Screen antibody repositories (e.g., R&D Systems, Human Protein Atlas) using corrected nomenclature.
-
Explore glycoprotein-targeting antibodies, as aberrant glycosylation is a hallmark of cancer biomarkers .
